109

Lapatinib 250mg Tablets

Prescriber Criteria: Consultant Oncologist

Outpatient and Inpatient use:

1. Malignant Diseases

Reserved for the treatment of adult patients with breast cancer, whose tumours overexpress HER2:

• In combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy.

• In combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.

• In combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy.

Duration of Approval:

1 year